Stocks
Latest stock market news — earnings, indices, equities, and corporate events explained for retail investors.
1627 articles in Stocks — page 12 of 136
StocksCantor Fitzgerald Maintains Positive Outlook on JFrog Ahead of Earnings
Cantor Fitzgerald reaffirms an Overweight rating on JFrog, anticipating strong cloud growth and upcoming earnings.
StocksCantor Fitzgerald Maintains Positive Outlook on Docebo After Strong Q1 Results
Cantor Fitzgerald reaffirms its positive rating for Docebo following strong preliminary Q1 results.
StocksCantor Fitzgerald Maintains Positive Outlook on National Health Investors Following Portfolio Sale
Cantor Fitzgerald reaffirms an Overweight rating for National Health Investors after its $560 million portfolio sale.
StocksCantor Fitzgerald Increases Price Target for Netstreit Amid Positive Outlook
Cantor Fitzgerald raises Netstreit's price target to $24, citing increased investment expectations.
StocksECB Uncertain About Iran War's Economic Impact on Euro Zone
The ECB is waiting for more clarity on the Iran war's duration to assess its economic effects.
StocksUnlock InvestingPro for Under $7 a Month Before the Sale Ends
Take advantage of a limited-time offer for InvestingPro, featuring AI tools for stock analysis.
StocksAlfa Laval Reports Mixed Q1 2026 Results Amid Currency Challenges
Alfa Laval's Q1 2026 earnings show stable performance despite currency fluctuations and invoicing delays.
StocksGE Vernova Exceeds Earnings Expectations in Q1 2026
GE Vernova's Q1 2026 results show significant earnings and revenue growth, boosting investor confidence.
StocksStifel Maintains Buy Rating on Wolverine World Wide, Sets Price Target at $25
Stifel reaffirms its positive outlook on Wolverine stock, highlighting recovery and growth potential.
StocksStifel Maintains Buy Rating on Danaher, Sets Price Target at $260
Stifel reaffirms its Buy rating for Danaher Corp, noting mixed quarterly results but positive long-term outlook.
StocksStifel Maintains Buy Rating on Zymeworks Amid Positive Drug Data
Stifel reaffirms a Buy rating for Zymeworks after promising data on its ZW191 drug candidate.
StocksBofA Maintains Buy Rating on GE Vernova Amid Strong Order Growth
BofA Securities reaffirms a Buy rating for GE Vernova, highlighting impressive order growth and financial performance.